Patents by Inventor Jin-Qiang Kuang
Jin-Qiang Kuang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240050482Abstract: This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: ApplicationFiled: January 26, 2023Publication date: February 15, 2024Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
-
Publication number: 20230381241Abstract: Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: ApplicationFiled: January 6, 2023Publication date: November 30, 2023Inventors: Samson TOM, Alla DANILKOVITCH, Dana YOO, Timothy JANSEN, Jin-Qiang KUANG, Jennifer Michelle MARCONI
-
Patent number: 11638725Abstract: Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: GrantFiled: February 8, 2019Date of Patent: May 2, 2023Assignee: OSIRIS THERAPEUTICS, INC.Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
-
Publication number: 20230128936Abstract: Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: ApplicationFiled: October 24, 2022Publication date: April 27, 2023Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
-
Publication number: 20230113145Abstract: Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: ApplicationFiled: October 19, 2022Publication date: April 13, 2023Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
-
Patent number: 11590173Abstract: This invention provides a fluid therapeutic placental product comprising placental cells and a placental dispersion comprising placental factors. The placental cells and the placental dispersion are derived from placental tissue. A placental tissue can optionally be an amnion, chorion, or a trophoblast-depleted chorion. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: GrantFiled: April 6, 2020Date of Patent: February 28, 2023Assignee: OSIRIS THERAPEUTICS, INC.Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
-
Patent number: 11590172Abstract: Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: GrantFiled: March 8, 2019Date of Patent: February 28, 2023Assignee: OSIRIS THERAPEUTICS, INC.Inventors: Samson Tom, Alla Danilkovitch, Dana YOo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
-
Publication number: 20230047934Abstract: Disclosed are compositions comprising a minced chorionic matrix, a homogenized amniotic matrix, and a homogenized umbilical cord (UC) matrix, wherein the minced chorionic matrix comprises viable cells, wherein the composition does not comprise trophoblasts. Disclosed are compositions comprising isolated, viable chorionic cells, a homogenized amniotic matrix, and a homogenized UC matrix, wherein the composition does not comprise trophoblasts. Disclosed are compositions comprising a minced chorionic matrix and a homogenized UC matrix, wherein the minced chorionic matrix comprises viable cells, wherein the composition does not comprise trophoblasts or an amniotic matrix. Disclosed are compositions comprising isolated, viable chorionic cells and a homogenized UC matrix, wherein the composition does not comprise trophoblasts or an amniotic matrix.Type: ApplicationFiled: March 12, 2021Publication date: February 16, 2023Applicant: Osiris Therapeutics, Inc.Inventors: Steven Michael SINCLAIR, Alla DANILKOVITCH, Malathi SATHYAMOORTHY, Jin-Qiang KUANG, Sandeep DHALL, Yishan LIU, Anthony John MELCHIORRI, Matthew Robert MOORMAN, Mena Schiano LO MORIELLO, Anne Allgood LERCH
-
Patent number: 11510947Abstract: Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: GrantFiled: January 7, 2020Date of Patent: November 29, 2022Assignee: OSIRIS THERAPEUTICS, INC.Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
-
Publication number: 20220331485Abstract: A cryopreserved cartilage product is disclosed. The cryopreserved cartilage product can include a partially digested cryopreserved natural cartilage collagen matrix isolated from a subject. The collagen matrix can include viable cells embedded within the collagen matrix that are native to the collagen matrix and that were embedded in the collagen matrix when the collagen matrix was isolated from the subject, at least 70% of the embedded cells native to the collagen matrix can be viable in the cryopreserved cartilage product, and the partially digested collagen matrix can retain interaction between the collagen matrix and the native cells.Type: ApplicationFiled: June 30, 2022Publication date: October 20, 2022Inventors: Dana Sue Yoo, Jin-Qiang Kuang, Jaime Paden, Scott A. Maxson, Alla Danilkovitch, Erasmo Lopez, Samson Tom
-
Patent number: 11464809Abstract: Disclosed are compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. Also disclosed are compositions comprising a previously cryopreserved umbilical tissue, wherein after cryopreservation and subsequent thawing the umbilical tissue comprises: a) viable cells native to the umbilical tissue; b) tissue integrity of native umbilical tissue; c) one or more growth factors that are native to the umbilical tissue; and d) depleted amounts of one or more types of functional immunogenic cells. Disclosed are methods of producing compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. Also disclosed are methods of treating damaged tissue comprising administering to the site of the damaged tissue compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels.Type: GrantFiled: April 6, 2020Date of Patent: October 11, 2022Assignee: OSIRIS THERAPEUTICS, INC.Inventors: Alla Danilkovitch, Yi Duan-Arnold, Matthew Moorman, Anne Lerch, Jin-Qiang Kuang
-
Patent number: 11413373Abstract: This invention provides disrupted cartilage products, methods of manufacturing disrupted cartilage products, and methods of treating a subject comprising administering a cartilage product. The cartilage products are manufactured by a method comprising disrupting a collagen matrix, e.g. to produce a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic.Type: GrantFiled: September 26, 2014Date of Patent: August 16, 2022Assignee: OSIRIS THERAPEUTICS, INC.Inventors: Dana Sue Yoo, Jin-Qiang Kuang, Jaime Paden, Scott A. Maxson, Alla Danilkovitch, Erasmo Lopez, Samson Tom
-
Patent number: 11406735Abstract: This invention provides porated cartilage products and methods of producing porated cartilage products. Optionally, the cartilage products are sized, porated, and digested to provide a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic.Type: GrantFiled: September 12, 2014Date of Patent: August 9, 2022Assignee: OSIRIS THERAPEUTICS, INC.Inventors: Dana Sue Yoo, Jin-Qiang Kuang, Jaime Paden, Scott A. Maxson, Alla Danilkovitch, Erasmo Lopez, Samson Tom
-
Publication number: 20220202991Abstract: Provided herein is a bone repair composition that is composed of periosteum containing an angiogenic growth factor(s), cancellous bone chips containing viable osteogenic cells, and, optionally, demineralized bone matrix (DBM) chips. Also provided herein are articles of manufacture and methods of use thereof to treat bone defects.Type: ApplicationFiled: March 18, 2022Publication date: June 30, 2022Inventors: Thomas E. UVEGES, Jin-Qiang KUANG, Alla DANILKOVITCH, S. Michael SINCLAIR, Sandra D. GERAGHTY
-
Publication number: 20220202876Abstract: Disclosed are methods of lyophilizing a tissue sample comprising obtaining a tissue sample, contacting the tissue sample with a lyoprotectant solution, freezing the tissue sample, performing a first drying step of the tissue sample after freezing, and performing a second drying step of the tissue sample after the first drying step. Disclosed are lyophilized tissues prepared using the disclosed methods of lyophilizing a tissue sample comprising obtaining a tissue sample, contacting the tissue sample with a lyoprotectant solution, freezing the tissue sample, performing a first drying step of the tissue sample after freezing, and performing a second drying step of the tissue sample after the first drying step. Disclosed are methods of treating a wound or tissue defect comprising administering a reconstituted lyophilized tissue to the wound or tissue defect.Type: ApplicationFiled: March 18, 2022Publication date: June 30, 2022Inventors: Steven Michael SINCLAIR, Alla DANILKOVITCH, Malathi SATHYAMOORTHY, Jin-Qiang KUANG, Sandeep DHALL, Anthony John MELCHIORRI
-
Publication number: 20220184277Abstract: This invention provides porated cartilage products and methods of producing porated cartilage products. Optionally, the cartilage products are sized, porated, and digested to provide a flexible cartilage product. Optionally, the cartilage products comprise viable chondrocytes, bioactive factors such as chondrogenic factors, and a collagen type II matrix. Optionally, the cartilage products are non-immunogenic.Type: ApplicationFiled: February 25, 2022Publication date: June 16, 2022Inventors: Dana Sue YOO, Jin-Qiang KUANG, Jaime PADEN, Scott A. MAXSON, Alla DANILKOVITCH, Erasmo LOPEZ, Samson TOM
-
Patent number: 11318168Abstract: Disclosed are compositions comprising a non-homogenized chorionic matrix, a homogenized amniotic matrix and a homogenized UC (UC) matrix, wherein the non-homogenized chorionic matrix comprises viable cells. Disclosed are methods of making the compositions disclosed herein comprising preparing a non-homogenized chorionic matrix, preparing a homogenized amniotic matrix, preparing a homogenized UC matrix, and combining the non-homogenized chorionic matrix, the non-homogenized chorionic matrix, and the homogenized UC matrix. Disclosed are methods of treating a tissue injury or chronic pain comprising administering any of the disclosed compositions to an area of a subject comprising a tissue injury.Type: GrantFiled: June 23, 2017Date of Patent: May 3, 2022Assignee: OSIRIS THERAPEUTICS, INC.Inventors: Steven Michael Sinclair, Alla Danilkovitch, Malathi Sathyamoorthy, Jin-Qiang Kuang, Sandeep Dhall, Yishan Liu, Anthony John Melchiorri, Matthew Robert Moorman, Mena Schiano Lo Moriello, Anne Allgood Lerch
-
Publication number: 20220016180Abstract: Disclosed are compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. Also disclosed are compositions comprising a previously cryopreserved umbilical tissue, wherein after cryopreservation and subsequent thawing the umbilical tissue comprises: a) viable cells native to the umbilical tissue; b) tissue integrity of native umbilical tissue; c) one or more growth factors that are native to the umbilical tissue; and d) depleted amounts of one or more types of functional immunogenic cells. Disclosed are methods of producing compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels. Also disclosed are methods of treating damaged tissue comprising administering to the site of the damaged tissue compositions comprising umbilical tissue, wherein the umbilical tissue comprises one or more engineered channels.Type: ApplicationFiled: August 12, 2021Publication date: January 20, 2022Inventors: Alla DANILKOVITCH, Yi DUAN-ARNOLD, Matthew MOORMAN, Anne LERCH, Jin-Qiang KUANG
-
Patent number: 11207353Abstract: Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: GrantFiled: March 8, 2019Date of Patent: December 28, 2021Assignee: OSIRIS THERAPEUTICS, INC.Inventors: Samson Tom, Alla Danilkovitch, Dana Yoo, Timothy Jansen, Jin-Qiang Kuang, Jennifer Michelle Marconi
-
Publication number: 20210369784Abstract: Provided herein is a placental product comprising an immunocompatible amniotic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.Type: ApplicationFiled: August 13, 2021Publication date: December 2, 2021Inventors: Samson TOM, Alla DANILKOVITCH, Dana YOO, Timothy JANSEN, Jin-Qiang KUANG, Jennifer Michelle MARCONI